OBJECTIVE: To investigate the loudness dependence of the auditory evoked potential (LDAEP) in predicting response to treatment for major depression. METHODS: One hundred patients of Chinese ethnicity with major depression were divided into 2 groups, having strong or weak pretreatment LDAEP; the cutoff was the median of the LDAEP slope (for amplitude as a function of intensity). There were no between-group differences before treatment in terms of score on the Hamilton Depression Rating Scale (HDRS), age or sex distribution. The LDAEP for 4 intensity levels (60, 70, 80 and 90 dB) was recorded before treatment. Each patient then received fluoxetine 20 mg per day for 4 weeks. The response to treatment was evaluated by means of the HDRS. RESULTS: At week 4, the HDRS score had declined by 44.3; for the group with strong LDAEP and by 34.4% for the group with weak LDAEP (t for mean difference = 2.584, p = 0.011). CONCLUSION: Strong pretreatment LDAEP predicted a favourable response to treatment with a selective serotonin reuptake inhibitor in patients with major depression.
OBJECTIVE: To investigate the loudness dependence of the auditory evoked potential (LDAEP) in predicting response to treatment for major depression. METHODS: One hundred patients of Chinese ethnicity with major depression were divided into 2 groups, having strong or weak pretreatment LDAEP; the cutoff was the median of the LDAEP slope (for amplitude as a function of intensity). There were no between-group differences before treatment in terms of score on the Hamilton Depression Rating Scale (HDRS), age or sex distribution. The LDAEP for 4 intensity levels (60, 70, 80 and 90 dB) was recorded before treatment. Each patient then received fluoxetine 20 mg per day for 4 weeks. The response to treatment was evaluated by means of the HDRS. RESULTS: At week 4, the HDRS score had declined by 44.3; for the group with strong LDAEP and by 34.4% for the group with weak LDAEP (t for mean difference = 2.584, p = 0.011). CONCLUSION: Strong pretreatment LDAEP predicted a favourable response to treatment with a selective serotonin reuptake inhibitor in patients with major depression.
Authors: B G Pollock; R E Ferrell; B H Mulsant; S Mazumdar; M Miller; R A Sweet; S Davis; M A Kirshner; P R Houck; J A Stack; C F Reynolds; D J Kupfer Journal: Neuropsychopharmacology Date: 2000-11 Impact factor: 7.853
Authors: S Battersby; A D Ogilvie; C A Smith; D H Blackwood; W J Muir; J P Quinn; G Fink; G M Goodwin; A J Harmar Journal: Psychiatr Genet Date: 1996 Impact factor: 2.458
Authors: J Gallinat; R Bottlender; G Juckel; A Munke-Puchner; G Stotz; H J Kuss; P Mavrogiorgou; U Hegerl Journal: Psychopharmacology (Berl) Date: 2000-03 Impact factor: 4.530
Authors: M T Carrillo-de-la-Peña; P Mavrogiorgou; G Juckel; W Hauke; J Gallinat; T Frodl; M Zaudig; U Hegerl Journal: Psychiatry Res Date: 2000-04-10 Impact factor: 3.222
Authors: I Hui Lee; Yen Kuang Yang; Po See Chen; Hui Chun Huang; Tzung Lieh Yeh; Ru-Band Lu; Nan-Tsing Chiu; Wei Jen Yao; Shih-Hsien Lin Journal: Psychopharmacology (Berl) Date: 2010-11-12 Impact factor: 4.530
Authors: Craig E Tenke; Jürgen Kayser; Pia Pechtel; Christian A Webb; Daniel G Dillon; Franziska Goer; Laura Murray; Patricia Deldin; Benji T Kurian; Patrick J McGrath; Ramin Parsey; Madhukar Trivedi; Maurizio Fava; Myrna M Weissman; Melvin McInnis; Karen Abraham; Jorge E Alvarenga; Daniel M Alschuler; Crystal Cooper; Diego A Pizzagalli; Gerard E Bruder Journal: Psychophysiology Date: 2017-01 Impact factor: 4.016
Authors: Barry V O'Neill; Rodney J Croft; Sumie Leung; Chris Oliver; K Luan Phan; Pradeep J Nathan Journal: Psychopharmacology (Berl) Date: 2007-07-24 Impact factor: 4.530